Oral Oncology
Volume 39, Issue 3 , Pages 301-305, April 2003

Fibrous dysplasia in the maxilla: possible mechanism of bone remodeling by calcitonin treatment

Department of Oral and Maxillofacial Surgery, Gifu University School of Medicine, 40 Tsukasamachi, Gifu 500-8705, Japan

Received 25 March 2002; accepted 5 June 2002.

published electronically DATE TO BE ADVISED

Abstract 

The long-term follow-up case of monostotic fibrous dysplasia of the maxilla in a 10-year-old girl is described with her endocrinologic data and therapeutic consequence of calcitonin administration in association with surgical interventions. The fibrous dysplasia tends to become more quiescent or static after skeletal growth ceases, but the causative has been still unknown to date. In this case reported changes of calciotropic hormones in the serum were well corresponding to the ceasing of the tumor growth at the puberty and reflected to the calcitonin administration. Although calcitonin has been applied to the fibrous dysplasia associated with McCune Albright syndrome, no histologic changes have been described after the calcitonin treatment. This report might be the first description of bone remodeling after the calcitonin treatment for the fibrous dysplasia of the maxilla in immature people. Data of this case may provide a clue to the pathogenesis of fibrous dysplasia. Surgical intervention can be performed after the local bone calcification by a calcitonin treatment, because of alleviation of vigorous hemorrhage by the bone remodeling.

Keywords:  Fibrous dysplasia, Maxilla, Parathyroid hormone/parathyroid hormone-related peptide, Calcitonin, Bone remodeling

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-8375(02)00037-4

doi:10.1016/S1368-8375(02)00037-4

Oral Oncology
Volume 39, Issue 3 , Pages 301-305, April 2003